Every 10-K that ALLURION TECHNOLOGIES INC (ALUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALUR filings page.
Allurion Technologies, Inc. describes its business as a metabolically focused weight loss platform built around the Allurion Program, which combines the swallowable Allurion Smart Capsule gastric balloon with an AI-powered Virtual Care Suite for remote monitoring and behavior change.
The company highlights more than 200,000 patients treated across over 50 countries and positions its program as complementary to GLP-1 drugs. It reports FDA PMA approval in the United States for the Allurion Gastric Balloon System for adults with obesity, enabling U.S. commercialization. Recent financing steps include a November 2025 private placement and a February 2026 warrant inducement that raised cash but added new warrants.
Allurion also discloses NYSE minimum market-capitalization non-compliance and ongoing appeals of delisting determinations, with its common stock now trading on the OTC market and plans to seek a higher-tier OTC listing. The company emphasizes a large obesity market opportunity, a broad patent and trademark portfolio, and a strategy focused on global expansion, U.S. launch, and a path to profitability.
Allurion Technologies (ALUR) amended its annual report to reflect a reverse stock split, the close of a business combination with Compute Health, and several financing and restructuring items. The filing discloses continued net operating losses and significant debt, including a $40.0 million upfront Revenue Interest Financing that requires royalty-style payments of up to 6.0% of annual net sales through 2026 and up to 10.0% thereafter through 2030. The company is restating prior financial statements and discloses material weaknesses in disclosure controls and internal control over financial reporting. The Allurion Balloon remains unapproved for commercial sale in the U.S.; the company is conducting an FDA IDE trial (AUDACITY) to support a future PMA. Operationally, Allurion reports commercialization in over 50 countries, a connected patient App and scale, an AI-powered clinic dashboard (Allurion Insights/Allurion Iris AI), and plans to expand its product label, geographic reach, and SaaS offerings. The filing lists numerous risk factors including regulatory, clinical, supply-chain, litigation, liquidity and market-acceptance risks that may materially affect results.
Allurion Technologies (ALUR) amended its annual report describing strategic, operational and financial risks tied to its post‑merger transition and commercialization of the Allurion Balloon. The company completed a Business Combination with Compute Health and various financings including a July 1, 2024 public offering that raised net proceeds of $15.2 million and multiple private placements. Allurion sells the Allurion Balloon and an AI‑powered Virtual Care Suite (VCS) in over 40 countries but the Balloon is not approved for commercial sale in the U.S. The filing discloses a restatement of prior financial statements, material weaknesses in internal controls, significant debt and revenue‑interest financing with RTW that carries contingent payment rates and covenants. The company states it has incurred losses and expects losses to continue while FDA approval, regulatory compliance, NYSE cure planning, supply, and reimbursement risks remain material.